Tech Company Financing Transactions

Shoreline Biosciences Funding Round

Shoreline Biosciences secured a $140 million financing round on 11/3/2021. Investors included Ally Bridge Group, BeiGene and Boxer Capital.

Transaction Overview

Announced On
11/3/2021
Transaction Type
Venture Equity
Amount
$140,000,000
Round
Undisclosed
Investors

Ally Bridge Group (Lead Investor) (Frank Yu)

BeiGene

Boxer Capital (Christopher Fuglesang)

BVF Partners

Commodore Capital

Cormorant Asset Management

Eventide Asset Management

Gilead Sciences

Irving Investors

Janus Henderson Investors

Kingdon Capital

NS Investment

Piper Sandler

Stork Capital

Superstring Capital

Wedbush Securities

Proceeds Purpose
The proceeds from the financing will allow Shoreline to continue the advancement of its proprietary iPSC platform focused on developing next generation natural killer (NK) cell and macrophage-cell therapies, create potent and persistent NK cell-specific Chimeric Antigen Receptors (CARs) as well as switchable CAR-NK cell engagers and macrophage-specific CARs to treat blood cancers, solid tumors, and other health conditions.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11408 Sorrento Valley Rd.
San Diego, CA 92121
USA
Phone
Undisclosed
Email Address
Overview
To establish safe, effective, and affordable cell-based immunotherapies for the treatment of seriously ill patients. Through innovative thinking and tenacity we strive to discover and develop clinically effective immunotherapies using intelligently engineered iPSC-derived allogeneic cells to save lives.
Profile
Shoreline Biosciences LinkedIn Company Profile
Social Media
Shoreline Biosciences Company Twitter Account
Company News
Shoreline Biosciences News
Facebook
Shoreline Biosciences on Facebook
YouTube
Shoreline Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chairman
Kleanthis Xanthopoulos
  Kleanthis Xanthopoulos LinkedIn Profile  Kleanthis Xanthopoulos Twitter Account  Kleanthis Xanthopoulos News  Kleanthis Xanthopoulos on Facebook
Co-Founder
Steven Holtzman
  Steven Holtzman LinkedIn Profile  Steven Holtzman Twitter Account  Steven Holtzman News  Steven Holtzman on Facebook
Co-Founder
Daniel Kaufman
  Daniel Kaufman LinkedIn Profile  Daniel Kaufman Twitter Account  Daniel Kaufman News  Daniel Kaufman on Facebook
Co-Founder
William Sandborn
  William Sandborn LinkedIn Profile  William Sandborn Twitter Account  William Sandborn News  William Sandborn on Facebook


 

 

Browse more venture capital transactions:

Prev: 11/3/2021: Archive.ai venture capital transaction
Next: 11/3/2021: Cambridge Epigenetix venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

We do our best to record every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary